Inhibition of key enzymes implicated in neurological disorders, including AChE, BChE, beta-secretase and monoamine oxidase, has been identified as a promising approach towards developing neurotherapeutic agents (Murray et al. 2013). The gene discussed is ACHE; the disease is nervous system disorder.